Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
431.12
-8.22 (-1.87%)
Mar 6, 2026, 10:02 AM EST - Market open
Madrigal Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 958.4 | 180.13 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 432.05% | - | - | - | - | Upgrade
|
| Cost of Revenue | 56.15 | 6.23 | - | - | - | Upgrade
|
| Gross Profit | 902.26 | 173.9 | - | - | - | Upgrade
|
| Selling, General & Admin | 813.83 | 435.06 | 108.15 | 48.13 | 37.32 | Upgrade
|
| Research & Development | 388.53 | 236.72 | 272.35 | 245.44 | 205.16 | Upgrade
|
| Operating Expenses | 1,202 | 671.78 | 380.5 | 293.57 | 242.48 | Upgrade
|
| Operating Income | -300.1 | -497.88 | -380.5 | -293.57 | -242.48 | Upgrade
|
| Interest Expense | -22.31 | -14.67 | -12.71 | -3.96 | - | Upgrade
|
| Interest & Investment Income | 37.36 | 46.65 | 19.58 | 2.19 | 0.36 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.46 | - | - | - | 0.27 | Upgrade
|
| EBT Excluding Unusual Items | -285.51 | -465.89 | -373.63 | -295.35 | -241.85 | Upgrade
|
| Other Unusual Items | -2.78 | - | - | - | - | Upgrade
|
| Pretax Income | -288.28 | -465.89 | -373.63 | -295.35 | -241.85 | Upgrade
|
| Net Income | -288.28 | -465.89 | -373.63 | -295.35 | -241.85 | Upgrade
|
| Net Income to Common | -288.28 | -465.89 | -373.63 | -295.35 | -241.85 | Upgrade
|
| Shares Outstanding (Basic) | 22 | 21 | 19 | 17 | 17 | Upgrade
|
| Shares Outstanding (Diluted) | 22 | 21 | 19 | 17 | 17 | Upgrade
|
| Shares Change (YoY) | 5.46% | 13.83% | 9.05% | 3.64% | 7.05% | Upgrade
|
| EPS (Basic) | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 | Upgrade
|
| EPS (Diluted) | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 | Upgrade
|
| Free Cash Flow | -190.02 | -457.03 | -325.71 | -225.07 | -184.13 | Upgrade
|
| Free Cash Flow Per Share | -8.47 | -21.48 | -17.43 | -13.13 | -11.13 | Upgrade
|
| Gross Margin | 94.14% | 96.54% | - | - | - | Upgrade
|
| Operating Margin | -31.31% | -276.39% | - | - | - | Upgrade
|
| Profit Margin | -30.08% | -258.64% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -19.83% | -253.72% | - | - | - | Upgrade
|
| EBITDA | -298.59 | -496.78 | -379.97 | -293.1 | -242.08 | Upgrade
|
| EBITDA Margin | -31.16% | -275.78% | - | - | - | Upgrade
|
| D&A For EBITDA | 1.51 | 1.1 | 0.53 | 0.47 | 0.41 | Upgrade
|
| EBIT | -300.1 | -497.88 | -380.5 | -293.57 | -242.48 | Upgrade
|
| EBIT Margin | -31.31% | -276.39% | - | - | - | Upgrade
|
| Advertising Expenses | 145.1 | 52.7 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.